Antengene Announces Strategic Collaboration with MindRank AI to Advance First-in-Class Small Molecule Oncology Drug Discovery

SHANGHAI, China and HONG KONG – August 9, 2021 – Antengene Corporation (“Antengene”, 6996.HK), a leading biopharmaceutical company dedicated to the research, development, and commercialization of innovative oncology therapies, and MindRank AI, an AI drug discovery company, today announced a long-term strategic collaboration to jointly advance the research and development of first-in-class small-molecule anti-tumor drugs. To date, MindRank AI has already contributed to the development of one of Antengene’s preclinical candidate drugs.

This collaboration marks a powerful partnership between a leading R&D-driven biopharmaceutical platform and an AI drug discovery platform dedicated to innovation. ANTENGENE CORPORATION boasts a professional team with extensive experience in global clinical drug development, capable of conducting in-depth research on the development of therapeutics targeting difficult-to-drug targets. Currently, ANTENGENE CORPORATION has 13 products in its pipeline, among which 5 hold rights for the Asia-Pacific region, including the Greater China market, and 8 hold global rights. MindRank will leverage its proprietary one-stop AI drug discovery platform, Molecule Pro™, and molecular dynamics platform, Molecule Dance™, to assist ANTENGENE CORPORATION in designing and identifying more candidate drugs with "first-in-class" and "best-in-class" potential.

This collaboration between ANTENGENE CORPORATION and MindRank on undruggable target projects aims to enhance the efficiency and success rate of current drug development, provide patients with breakthrough therapeutic solutions, and address more unmet medical needs.

Dr. Mei Jianming, Founder, Chairman and Chief Executive Officer of ANTENGENE CORPORATION, stated: “This breakthrough collaboration with MindRank on undruggable targets is undoubtedly exciting news. Over the past four years, through in-licensing and in-house R&D, Antengene has established a development pipeline comprising 13 drug candidates. In 2021, the first innovative drug independently developed by Antengene’s R&D team entered clinical trials as scheduled. We believe this powerful partnership will provide strong impetus to Antengene’s independent R&D, and deliver newer, broader, and more effective clinical treatment options to patients globally.”

Niu Zhangming, Founder and Chief Executive Officer of MindRank, stated: "We are honored to become strategic partners with Antengene Corporation. Antengene possesses outstanding R&D capabilities, and its founding core team has proven expertise in the development and commercialization of globally best-selling oncology drugs. We eagerly look forward to synergizing the successful experience of the Antengene team with MindRank's AI-driven drug discovery platform to jointly advance the R&D of more first-in-class anti-tumor drugs for patients worldwide. We are committed to making more diseases treatable with available therapies and helping more patients regain their health."

Responsible Editor: Liuli

Disclaimer: This article is reproduced content from Yaozhi Network. The copyright belongs to the original author(s). It is shared for the purpose of conveying additional information and does not represent the views of this platform. Should there be any issues concerning the content, copyright, or other matters, please contact us by leaving a message on this website. We will remove the content immediately!